## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re A	applicat	ion of: Nikolai (Mykola) IGNATYEV e	t al.			
Serial	No.: 10	0/568,526	Group Art Unit: 1626			
Filed:	Februa	ry 17, 2006	Examiner: Fiona Powers			
For:		NOBORATE, FLUOROALKYLPHOSPHATE E DYES	E, FLUOROALKYLBORATE OR			
INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98						
P.O. B	ox 145	or for Patents 0 7A 22313-1450				
	This ir 98 as fo	nformation disclosure statement is made in acco	ordance with 37 C.F.R. §§ 1.56, 1.97			
Timing and Fees						
		37 C.F.R. § 1.97(b), no fee or statement is resure statement is filed:	equired for filing this information			
		within three months of the filing date of a nat under § 1.53(d);	ional application other than a CPA			
		within three months of the actual filing dat application; OR	e of the national phase of a PCT			
		before the mailing of a first substantive office RCE).	e action (including after filing of an			
		37 C.F.R. § 1.97(c), this information disclosure ied in 37 C.F.R. § 1.97(b), but before the maili	*			
		a final rejection under 37 C.F.R. 1.113; termination of prosecution, e.g. Ex Parte Qua a notice of allowance under 37 C.F.R. § 1.31				

		is accompanied by:			
			the statement as specified in 37 C.F.R. § 1.97(e) set out below;		
			a check covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or		
			payment by credit card via EFS covering the fee of \$180.00 under 37 C.F.R. § 1.17(p); or		
$\boxtimes$		Under 37 C.F.R. § 1.97(d), this information disclosure statement is filed after the mailing date of the following actions which have not been withdrawn:			
		a final	action under 37 C.F.R. § 1.113;		
		termin	ation of prosecution, e.g. Ex Parte Quayle, M.P.E.P § 609(B)(2);		
	$\boxtimes$	OR a r	notice of allowance under 37 C.F.R. § 1.311;		
	AND i	s filed o	on or before payment of the issue fee; AND is accompanied by:		
			tement as specified in 37 C.F.R. § 1.97(e) as set forth below, and the fee of 00 under 37 C.F.R. § 1.17(p).		
Staten	nents U1	nder 37	C.F.R. 1.97(e)		
			Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application having a mailing date not more than three months prior to the filing date of this information disclosure statement; or		
			No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and to the knowledge of the undersigned attorney after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing date of the information disclosure statement.		
Cited 1	Materia	<u>ls</u>			
		ancest	s of materials listed but not attached were cited in benefit (35 U.S.C. § 120) or application Serial No, on Form 892 by the Examiner and/or Form by the applicant; see 37 C.F.R. § 1.98(d).		
		_	s of materials listed but not attached were cited in an international search dated		

	Not required by 37 CFR § 1.98.				
	Copies of the materials listed are attached (except for the foregoing).				
Non-Eng	lish Language References				
	An English-language search report or equivalent paper from a foreign patent office is provided indicating the relevance of the cited reference(s).				
	A foreign-language search report from a foreign patent office is provided, and pertinent parts are translated substantively below:				
	<ul> <li>X = document of particular relevance when it is taken alone</li> <li>Y = document of particular relevance when it is combined with another such document</li> <li>A = document defining the general state of the art</li> <li>O = non-written disclosure</li> <li>P = intercalated document</li> <li>T = document cited to understand the theory or principle underlying the invention</li> <li>E = patent document which has the benefit of a date earlier than the filing date and which was published only on or after this filing date</li> <li>D = cited in the application</li> <li>L = cited for another reason</li> <li>&amp; = publication of member of same patent family</li> </ul> Translation of other relevant information on foreign search report				
×	Other Information				
TI	The following references were cited in an Office Action issued November				
22, 2010	in corresponding European Patent Application No. EP 10008076.1:				
El X	EP 0 055 223; EP 0 636 493; X. Yang; Journal American Chemical Society, 114:793-794 (1992); and H. Iwamoto; Bull. Chem. Soc. Japan, 56(3):796-801 (1983).				
	opies of these references are enclosed. Also enclosed is U.S. 4,367,334 orresponds to EP 0 055 223).				

Also, the following references were cited in an Office Action issued

August 31, 2010 in corresponding Japanese Application Publication No. JP 2007-503477: JP H08-253 705 (corresponding to US 5,541,235); JP H04077503; M.C. Etter et al., Israel Journal of Chemistry, 1985, Vol. 25, No. 3-4, pp 2645-273; Zhu et al., Inorganic Chemistry, 1993, Vol. 32, No. 2, pp 223-226; Pavlenko et al., Zhurnal Obshchei Khimii, 1989, Vol. 59, No. 3, pp 528-534; and US 3,567,453. Payment of Fees Due (If Any): A check for \$ covering the fee identified above is attached.  $\boxtimes$ Payment by credit card via EFS for \$180.00 covering the fee identified above. Please charge to Deposit Account No. 13-3402 \$\_\_\_\_\_ for the fee identified above.  $\boxtimes$ The Commissioner is hereby authorized to charge or credit any overpayment to Deposit Account #13-3402. Respectfully submitted, /Brion P.Heaney/ Brion P. Heaney, Reg. No. 32,542 Attorney/Agent for Applicants MILLEN, WHITE, ZELANO & BRANIGAN, P.C. Arlington Courthouse Plaza 1 2200 Clarendon Blvd. Suite 1400 Arlington, Virginia 22201 Telephone: (703) 243-6333 Facsimile: (703) 243-6410 Attorney Docket No.: MERCK-3134 Date: January 21, 2011 BPH:dap